Market Place
Sourcing Support
Tourmaline Sees Positive Phase 2 Data in CKD Inflammation Trial
20 May 2025 //
GLOBENEWSWIRE
Tourmaline Bio to Present Phase 2 Trial Results on May 20, 2025
19 May 2025 //
GLOBENEWSWIRE
Tourmaline Bio Reports Q1 2025 Financials and Business Highlights
02 May 2025 //
GLOBENEWSWIRE
Tourmaline Bio Reports Q4 and Full Year 2024 Financial Results
13 Mar 2025 //
GLOBENEWSWIRE
Tourmaline To Present At Leerink Partners 2025 Conference
03 Mar 2025 //
GLOBENEWSWIRE
Tourmaline Bio To Present At Guggenheim SMID Cap Biotech
27 Jan 2025 //
GLOBENEWSWIRE
Tourmaline Add Dr. Paul To Cardiovascular Scientific Advisory Board
10 Jan 2025 //
GLOBENEWSWIRE
Tourmaline Updates On Cardiovascular Focus At Investor Day
10 Dec 2024 //
GLOBENEWSWIRE
Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024
14 Nov 2024 //
GLOBENEWSWIRE
Tourmaline Bio Q3 2024 Results & Recent Business Updates
07 Nov 2024 //
GLOBENEWSWIRE
Tourmaline To Host Webinar On IL-6 Inhibition In Cardio Disease
15 Oct 2024 //
GLOBENEWSWIRE
Tourmaline To Showcase 2 Presentations At 2024 Cardiometabolic
11 Oct 2024 //
GLOBENEWSWIRE
Tourmaline Bio Forms Cardiovascular Scientific Advisory Board
08 Oct 2024 //
GLOBENEWSWIRE
Tourmaline Bio to Present at Upcoming Investor Conferences
03 Sep 2024 //
GLOBENEWSWIRE
Tourmaline Bio Reports Q2 2024 Results And Business Highlights
08 Aug 2024 //
GLOBENEWSWIRE
Tourmaline Bio Presents TRANQUILITY Study Design At ASPC Congress 2024
02 Aug 2024 //
GLOBENEWSWIRE
Tourmaline Bio Announces the Promotion of Ryan Robinson to CCFO
27 Jun 2024 //
GLOBENEWSWIRE
Tourmaline Bio to Present at the Jefferies Global Healthcare Conference
23 May 2024 //
GLOBENEWSWIRE
Tourmaline Bio Doses First Patient In TOUR006 Cardiovascular Phase 2
16 May 2024 //
GLOBENEWSWIRE
Tourmaline Bio Reports Q1 2024 Results, Business Highlights
13 May 2024 //
GLOBENEWSWIRE
Tourmaline Bio Reports4Q FYR 2023 & Recent Business Highlights
19 Mar 2024 //
GLOBENEWSWIRE
Tourmaline Bio to Present at Upcoming Investor Conferences
27 Feb 2024 //
GLOBENEWSWIRE
Tourmaline Bio to Present at the 6th Annual Biotechnology Conference
01 Feb 2024 //
GLOBENEWSWIRE
Tourmaline Announces Closing of $172.5 Million Public Offering of Common Stock
29 Jan 2024 //
GLOBENEWSWIRE
Tourmaline Bio Announces Pricing of Public Offering of Common Stock
25 Jan 2024 //
GLOBENEWSWIRE
Tourmaline Bio Announces Proposed Public Offering of Common Stock
24 Jan 2024 //
GLOBENEWSWIRE
Tourmaline Bio Announces Key Milestones for Development of TOUR006
08 Jan 2024 //
GLOBENEWSWIRE
Tourmaline Bio added to the NASDAQ Biotechnology Index
15 Dec 2023 //
GLOBENEWSWIRE
Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board
14 Dec 2023 //
GLOBENEWSWIRE
Tourmaline Bio to Present at Upcoming Investor Conferences
01 Nov 2023 //
GLOBENEWSWIRE
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics
19 Oct 2023 //
GLOBENEWSWIRE
Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline
17 Oct 2023 //
GLOBENEWSWIRE
Talaris Declares Dividend In Connection with Proposed Merger with Tourmaline
06 Oct 2023 //
GLOBENEWSWIRE
Tourmaline Bio Appoints Gerhard Hagn as SVP
20 Sep 2023 //
GLOBENEWSWIRE
Tourmaline Bio Announces FDA Clearance of IND Application for TOUR006
28 Aug 2023 //
GLOBENEWSWIRE
